The use of cannabis in pharmaceuticals is estimated to transform the medical industry due to the properties of cannabis. The use of two components, such as CBD and THC have medicinal properties, which have been proved to treat health conditions such as epilepsy, schizophrenia, arthritis, multiple sclerosis, migraines. At present, across the world, more than 400 active and completed clinical trials are performed for cannabis-based medicinal products.
MARKET DYNAMICS
The cannabis pharmaceuticals market is anticipated to grow due to some driving factors, including the legalization of cannabis for medical applications, and increasing research and development for medical cannabis. The market is expected to have vital growth opportunities due to the growing adoption of cannabis for medical applications in Asian and Middle East countries, and rising product development by the pharmaceutical players.
MARKET SCOPE
The "Cannabis Pharmaceuticals Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of cannabis pharmaceuticals market with detailed market segmentation by product, and distribution channel. The cannabis pharmaceuticals market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in cannabis pharmaceuticals market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The cannabis pharmaceuticals market is segmented on the basis of product, and distribution channel. Based on product, the market is segmented as epidiolex, and sativex. And based on distribution channel, the market is divided as hospital pharmacies, online pharmacies, and retail pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Cannabis pharmaceuticals market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cannabis pharmaceuticals market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting cannabis pharmaceuticals market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Cannabis pharmaceuticals market in these regions.
MARKET PLAYERS
The report covers key developments in the cannabis pharmaceuticals market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from cannabis pharmaceuticals market are anticipated to have lucrative growth opportunities in the future with the rising demand for cannabis pharmaceuticals in the global market. Below mentioned is the list of few companies engaged in the cannabis pharmaceuticals market.
The report also includes the profiles of key players in cannabis pharmaceuticals market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Abbvie Inc.
- Insys Therapeutics, Inc.
- GW Pharmaceuticals
- Valeant Pharmaceuticals
- Tilray
- Cardiol Therapeutics
- Cure Pharmaceutical
- Zynerba Pharmaceuticals, Inc.
- Solvay Pharmaceuticals (Abbott)
- Indevus Pharmaceuticals
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.